ElectroCore, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 13, 2024 at 04:20 pm EDT
Share
electroCore, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 5.19 million compared to USD 2.56 million a year ago. Net loss was USD 4.03 million compared to USD 5.79 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 1.22 a year ago.
For the full year, the company reported sales was USD 16.03 million compared to USD 8.59 million a year ago. Net loss was USD 18.83 million compared to USD 22.16 million a year ago. Basic loss per share from continuing operations was USD 3.42 compared to USD 4.69 a year ago. Diluted loss per share from continuing operations was USD 3.42 compared to USD 4.69 a year ago.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
ELECTROCORE, INC. 
